⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 207 in last 7 days 🧸 Products: 73 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 5 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 207 in last 7 days 🧸 Products: 73 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 5 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT November 9, 2021

Farmorubicin 200 mg Stechampulle (Konzentrat zur Herstellung einer Infusionslösung)

📷 Wikipedia: Epirubicin · Source
Farmorubicin 200 mg Stechampulle (Konzentrat zur Herstellung einer Infusionslösung)
📷 Wikipedia: Epirubicin · Source
Farmorubicin 200 mg vial (concentrate for preparing an infusion solution) Parallel export ban in effect. Quality issues with bulk product. Affected packs: 1 vial [unavailable since 2021-11-04].
🗄
Archived (older alert)
This alert was reported 1663 days ago and has been moved from our active feed to the archive. The original safety information still applies — we have no confirmation from the issuing agency that the product is safe again. Refer to the official notice for the current status.
📈 Timeline
12 days in total
May 18, 2026 May 30, 2026
Daily snapshot data starts accumulating once the scheduler runs — for now this is interpolated from the agency's first/last dates.

What is this? This is a cancer medicine called epirubicin. It comes in a small bottle. Doctors use it in a drip to treat some cancers.

What's happening? One pack size of this medicine is not available right now. This has been true since November 2021.

Does this affect me? If your doctor has prescribed this exact pack size, you may be affected. This is only in Austria.

What should I do? Talk to your pharmacist or doctor before making any changes. They will help find the right treatment for you.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
EPIRUBICIN HYDROCHLORID
Agency-published detail

🚫 Parallel export ban active · ATC: L01DB03 · Reason: Qualitätsprobleme der Bulkware · Marketing authorisation holder: Pfizer Corporation Austria Ges.m.b.H., Floridsdorfer Hauptstraße 1, 1210 Wien, Österreich · Affected packs: 1 Stück Durchstechflasche [Nicht verfügbar, since 2021-11-04]

First published
November 9, 2021
Last refreshed by us
1 week ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Farmorubicin 200 mg Stechampulle (Konzentrat zur Herstellung einer Infusionslösung). Farmorubicin 200 mg vial (concentrate for preparing an infusion solution) Parallel export ban in effect. Quality issues with bulk product. Affected packs: 1 vial [unavailable since 2021-11-04].
▸ When was this alert issued?
This alert was issued on November 9, 2021 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.